Showing 761-770 of 836 results for "".
- Endo Launches New Consumer Campaign for Qwohttps://modernaesthetics.com/news/endo-launches-new-consumer-campaign-for-qwo/2473202/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- FDA Approves Mentor MemoryGel BOOST Breast Implanthttps://modernaesthetics.com/news/fda-approves-mentor-memorygel-boost-breast-implant/2473184/The Mentor® MemoryGel BOOST™ Breast Implant is now FDA approved for breast augmentation in women at least 22-years-old, and for women of all ages undergoing breast reconstruction. The product from Me
- Does the "No Surprises Act" Apply to Aesthetic Services?https://modernaesthetics.com/news/does-the-no-surprises-act-apply-to-aesthetic-services/2473180/In a chat thread with colleagues on our mutual trade organizations' message board, there was a question about providing Good Faith Estimates (GFE) for aesthetic procedures under the No Surprises Act. I stated that I didn't think GFEs were required for aesthetic procedures, but a represent
- Obagi Rolls Out The Skintrinsiq System Devicehttps://modernaesthetics.com/news/obagi-rolls-out-the-skintrinsiq-system-device/2473178/Obagi is launching the Skintrinsiq device, its first entry into the complementary skincare device market. The Skintrinsiq system extracts impurities then infuses Obagi skincare products via treatment protocols customized for individual skincare needs. "The uni
- 1 Million and Counting: Emsculpt Marks Treatment Milestonehttps://modernaesthetics.com/news/1-million-and-counting-emsculpt-marks-treatment-milestone/2473166/The Emsculpt family of products from BTL is the fastest aesthetic device brand to reach one million treatments, as indicated by Medical Insights. According to BTL, which reported the milestone, an average of 21 Emsculpt Classic treatments/unit a
- NeoGenesis Products Expand Beyond Oncology Skin Carehttps://modernaesthetics.com/news/neogenesis-products-expand-beyond-oncology-skin-care/2473164/NeoGenesis’ science-based skin and hair products have expanded from oncology aftercare to management of chronic skin conditions, aesthetic concerns, and wound support. The products were developed to provide a safe, natural approach to improving the quality of life of those undergoing oncolo
- Alastin Receives Two New Patents for Technology Related to TransFORM Body Treatmenthttps://modernaesthetics.com/news/alastin-receives-two-new-patents-for-technology-related-to-transform-body-treatment/2473148/With the issuance of two new patents from the United States Patent and Trademark Office, Alastin Skincare, Inc. now holds six patents in the US, along with a seventh patent issued in Canada. US Patent No.11,052,032 covers Alastin’s
- It’s Over: AbbVie, BTL Settle Muscle Stimulation Patent Disputehttps://modernaesthetics.com/news/its-over-abbvie-btl-settle-patent-dispute/2473143/BTL Industries has resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. Under the terms of the settlement agreement, AbbVie will pay BTL an undisclosed payment. The details of the agreement are confidential and will not be disc
- Alisa Lask Joins CollPlant’s Board of Directorshttps://modernaesthetics.com/news/alisa-lask-joins-collplants-board-of-directors/2473137/Industry vet Alisa Lask is now a member of CollPlant’s Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlan
- Study Tracks Increased Sadness, Fear, Disgust Among Healthcare Workers Linked to COVID-19https://modernaesthetics.com/news/study-tracks-increased-sadness-fear-disgust-among-healthcare-workers-linked-to-covid-19/2473134/Researchers discovered patterns of significantly decreased joy, increased sadness, fear and disgust among health care professionals (HCP) during the COVID-19 pandemic. The study, led by researchers at Ben-Gurion University of the